Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

Abstract Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully establi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Taichi Miyawaki, Hirotsugu Kenmotsu, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Acceso en línea:https://doaj.org/article/6452d84482df43b7a070b79879e835ef
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6452d84482df43b7a070b79879e835ef
record_format dspace
spelling oai:doaj.org-article:6452d84482df43b7a070b79879e835ef2021-11-21T12:30:40ZAssociation between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study10.1186/s12885-021-08983-21471-2407https://doaj.org/article/6452d84482df43b7a070b79879e835ef2021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08983-2https://doaj.org/toc/1471-2407Abstract Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. This study aimed to evaluate the predominant progressive disease (PD) pattern limited to residual sites of disease after treatment with EGFR-TKI. Methods Patients with advanced EGFR-mutated NSCLC treated with EGFR-TKIs as first-line therapy were retrospectively analysed during a 7-year period. Oligo-residual disease was defined as the presence of 1 – 4 lesions (including the primary site) at 3 months from the start of EGFR-TKI treatment. The predictive factors of PD patterns after EGFR-TKI treatment were evaluated. Results A total of 207 patients were included. Three months after the start of EGFR-TKI treatment, 66 patients (32%) had oligo-residual disease. A total of 191 patients had PD, 60 with oligo-residual disease and 131 with non-oligo-residual disease. Regarding the pattern, 44 patients (73%) with oligo-residual disease and 37 patients (28%) with non-oligo-residual disease had PD limited to the residual sites. Multivariate logistic regression analysis at 3 months from the start of EGFR-TKI treatment revealed that oligo-residual disease (P < 0.001), the lack of residual central nervous system metastases (P = 0.032), and initial treatment with osimertinib (P = 0.028) were independent predictors of PD limited to residual disease sites. Conclusions This study provided a rationale for LAT to all sites of residual disease in patients with oligo-residual disease during EGFR-TKI treatment.Taichi MiyawakiHirotsugu KenmotsuHiroaki KodamaNaoya NishiokaEriko MiyawakiNobuaki MamesayaHaruki KobayashiShota OmoriRyo KoKazushige WakudaAkira OnoTateaki NaitoHaruyasu MurakamiKeita MoriHideyuki HaradaMasahiro EndoKazuhisa TakahashiToshiaki TakahashiBMCarticleNon-small-cell lung cancerOligo-residual diseaseFailure patternEGFR-TKIOsimertinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
institution DOAJ
collection DOAJ
language EN
topic Non-small-cell lung cancer
Oligo-residual disease
Failure pattern
EGFR-TKI
Osimertinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle Non-small-cell lung cancer
Oligo-residual disease
Failure pattern
EGFR-TKI
Osimertinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Taichi Miyawaki
Hirotsugu Kenmotsu
Hiroaki Kodama
Naoya Nishioka
Eriko Miyawaki
Nobuaki Mamesaya
Haruki Kobayashi
Shota Omori
Ryo Ko
Kazushige Wakuda
Akira Ono
Tateaki Naito
Haruyasu Murakami
Keita Mori
Hideyuki Harada
Masahiro Endo
Kazuhisa Takahashi
Toshiaki Takahashi
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
description Abstract Background Local ablative therapy (LAT) may be beneficial for patients with epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) with oligo-residual disease after treatment with EGFR tyrosine kinase inhibitor (EGFR-TKI). However, this has not been fully established. This study aimed to evaluate the predominant progressive disease (PD) pattern limited to residual sites of disease after treatment with EGFR-TKI. Methods Patients with advanced EGFR-mutated NSCLC treated with EGFR-TKIs as first-line therapy were retrospectively analysed during a 7-year period. Oligo-residual disease was defined as the presence of 1 – 4 lesions (including the primary site) at 3 months from the start of EGFR-TKI treatment. The predictive factors of PD patterns after EGFR-TKI treatment were evaluated. Results A total of 207 patients were included. Three months after the start of EGFR-TKI treatment, 66 patients (32%) had oligo-residual disease. A total of 191 patients had PD, 60 with oligo-residual disease and 131 with non-oligo-residual disease. Regarding the pattern, 44 patients (73%) with oligo-residual disease and 37 patients (28%) with non-oligo-residual disease had PD limited to the residual sites. Multivariate logistic regression analysis at 3 months from the start of EGFR-TKI treatment revealed that oligo-residual disease (P < 0.001), the lack of residual central nervous system metastases (P = 0.032), and initial treatment with osimertinib (P = 0.028) were independent predictors of PD limited to residual disease sites. Conclusions This study provided a rationale for LAT to all sites of residual disease in patients with oligo-residual disease during EGFR-TKI treatment.
format article
author Taichi Miyawaki
Hirotsugu Kenmotsu
Hiroaki Kodama
Naoya Nishioka
Eriko Miyawaki
Nobuaki Mamesaya
Haruki Kobayashi
Shota Omori
Ryo Ko
Kazushige Wakuda
Akira Ono
Tateaki Naito
Haruyasu Murakami
Keita Mori
Hideyuki Harada
Masahiro Endo
Kazuhisa Takahashi
Toshiaki Takahashi
author_facet Taichi Miyawaki
Hirotsugu Kenmotsu
Hiroaki Kodama
Naoya Nishioka
Eriko Miyawaki
Nobuaki Mamesaya
Haruki Kobayashi
Shota Omori
Ryo Ko
Kazushige Wakuda
Akira Ono
Tateaki Naito
Haruyasu Murakami
Keita Mori
Hideyuki Harada
Masahiro Endo
Kazuhisa Takahashi
Toshiaki Takahashi
author_sort Taichi Miyawaki
title Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_short Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_full Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_fullStr Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_full_unstemmed Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
title_sort association between oligo-residual disease and patterns of failure during egfr-tki treatment in egfr-mutated non-small cell lung cancer: a retrospective study
publisher BMC
publishDate 2021
url https://doaj.org/article/6452d84482df43b7a070b79879e835ef
work_keys_str_mv AT taichimiyawaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT hirotsugukenmotsu associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT hiroakikodama associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT naoyanishioka associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT erikomiyawaki associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT nobuakimamesaya associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT harukikobayashi associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT shotaomori associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT ryoko associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT kazushigewakuda associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT akiraono associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT tateakinaito associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT haruyasumurakami associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT keitamori associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT hideyukiharada associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT masahiroendo associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT kazuhisatakahashi associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
AT toshiakitakahashi associationbetweenoligoresidualdiseaseandpatternsoffailureduringegfrtkitreatmentinegfrmutatednonsmallcelllungcanceraretrospectivestudy
_version_ 1718418947408134144